A new study has revealed that cancer rates will rise almost six times faster in women than in men over the next 20 years.
Cancer Research UK projects numbers will increase by around half a per cent for men and three per cent for women. Although more men are overweight, the "obesity timebomb hits women harder" because most cancers linked to weight tend to be more common in females, such as breast, womb and ovarian cancer, says the Daily Telegraph.
Widespread smoking among women happened later than in men, and smoking continues to have a big impact on the number of new cancer cases, according to Cancer Research UK.
Breast cancer is the second leading cause of death in women.
Georgetown Lombardi Comprehensive Cancer Center researchers have used animal models to reveal new information about the impact - positive and negative - that soy consumption could have on a common breast cancer treatment.
In what is believed to be the first large-scale study to quantify the development of breast cancer according to the degree of glandular tissue, which appears dense on mammogram, versus fat, which appears non-dense, researchers headed by UC San Francisco evaluated risk factors in more than 200,000 women.
"However, tamoxifen can have serious side effects and is generally only recommended for women at high risk of breast cancer, with guidance from their physician".
"Treatment with tamoxifen, an estrogen hormone blocker, is the only intervention now known that substantially reduces breast density and thus reduces breast cancer risk", said Engmann.
Smoking and drinking in women are linked with the increasing risk of lung, liver and mouth cancer. More people die from cancer than Aids, malaria and tuberculosis put together. Meanwhile, ovarian cancer cases will jump from nearly 7,400 to 10,500 while lung cancer cases rise from from 21,600 to nearly 30,000.
Amanda, 55, was diagnosed with advanced ovarian cancer in 2008, said: "It's unusual to survive for more than five years if you're diagnosed at a late stage like I was".
In draft guidance explaining its reasoning for its advice on palbociclib, which is made by Pfizer, the drug watchdog said that a full course of treatment costs £79,560. "Our results suggest that breast cancer patients should continue consuming soy foods after diagnosis, but not to start them if they have not consumed genistein previously".
"Palbociclib could benefit a large proportion of metastatic breast cancer patients and may even be the closest thing these women would have to a cure in their lifetime".
Past year a study suggested that the number of Britons set to develop cancer because they are overweight will treble within two decades. Baroness Delyth Morgan, of Breast Cancer Now, said it showed the system was totally "unfit for purpose". Although endocrine therapies can be highly effective in preventing or treating breast cancer, about half of patients who use them exhibit resistance and/or have cancer recurrence.
Researchers also found soy can boost the effect of the Tamoxifen by inhibiting a mechanism that helps cancer cells survive.